<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28618">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734173</url>
  </required_header>
  <id_info>
    <org_study_id>20150305-01H</org_study_id>
    <nct_id>NCT02734173</nct_id>
  </id_info>
  <brief_title>Pilot HCV DAA and Metabolism</brief_title>
  <acronym>3D</acronym>
  <official_title>Pilot Evaluation of the Influence of ABT450r, Ombitasvir, Dasabuvir +/- Ribavirin HCV Therapy on Insulin Resistance and Lipid Profile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is compelling data supporting the pursuit of research into the effects of HCV
      antivirals on metabolic homeostasis. As a further rationale and justification, the
      experience with HIV antiretrovirals has clearly demonstrated that antiviral medications can
      produce profound changes in glucose metabolism, lipid profile and other measures of
      metabolic homeostasis. This establishes biological plausibility for this focus of research
      in HCV.

      The new knowledge created from this research will:

        1. Provide new information on the metabolic effects of the Abbvie 3D HCV antiviral
           regimen.

        2. Provide insight as to whether there are metabolic advantages with RBV-free compared to
           RBV-containing HCV regimens. This is particularly relevant given the current
           uncertainty regarding the need for RBV in IFN-free, oral DAA regimens.

        3. Provide insight into the impact of cirrhosis on metabolic milieu before, during and
           after HCV antiviral therapy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pilot Evaluation of the Influence of ABT450r, Ombitasvir, Dasabuvir +/- Ribavirin Hepatitis C Antiviral Therapy on Insulin Resistance</measure>
    <time_frame>30 weeks</time_frame>
    <description>serial insulin sensitivity evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pilot Evaluation of the Influence of ABT450r, Ombitasvir, Dasabuvir +/- Ribavirin Hepatitis C Antiviral Therapy Lipid Homeostasis</measure>
    <time_frame>30 weeks</time_frame>
    <description>serial lipid homeostasis evaluation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Genotype 1a Non-Cirrhotic Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>• 8 non-cirrhotic genotype 1a-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy plus ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1b Non-Cirrhotic Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>• 8 non-cirrhotic genotype 1b-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy without ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1a/1b Compensated Cirrhotic Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>• 8 compensated cirrhotic genotype 1a or 1b-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy plus ribavirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT450r-ABT267-ABT333 +/- Ribavirin</intervention_name>
    <description>12 week duration of HCV antiviral therapy</description>
    <arm_group_label>Genotype 1a Non-Cirrhotic Arm</arm_group_label>
    <arm_group_label>Genotype 1b Non-Cirrhotic Arm</arm_group_label>
    <arm_group_label>Genotype 1a/1b Compensated Cirrhotic Arm</arm_group_label>
    <other_name>ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCV RNA evidence of HCV infection

          -  Documented history of chronic HCV RNA infection with Genotype 1

          -  Able to provide informed consent

          -  Available for ongoing follow-up if required

        Exclusion Criteria:

          -  &lt;18 years old

          -  Evidence of decompensated liver disease

          -  HOMA IR&lt; 2.0

          -  HIV seropositivity

          -  Chronic HBV/HIV infection

          -  Use of immune suppressing medications

          -  Active malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Ottawa Hospital, General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curtis Cooper, MD</last_name>
      <phone>613-737-8924</phone>
    </contact>
    <investigator>
      <last_name>Curtis Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 5, 2016</lastchanged_date>
  <firstreceived_date>October 21, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
